{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
penicillin v
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Thiohexamide is a first-generation, cyclohexyl-containing sulfonylurea with antihyperglycemic activity. The hypoglycemogenic activity of thiohexamide was detected in fasting, stable diabetic subjects.
Status:
Investigational
Source:
NCT02053272: Phase 2 Interventional Completed Diabetes Mellitus, Type 2
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tetrahydrocannabivarin is a propyl analogue of tetrahydrocannabinol that acts as a Cannabinoid receptor type 1 antagonist and a partial agonist of Cannabinoid receptor type 2. Beyond the endocannabinoid system, Tetrahydrocannabivarin has also been reported to activate 5HT1A receptors to produce an antipsychotic effect that has therapeutic potential for ameliorating some of the negative, cognitive and positive symptoms of schizophrenia. Animal studies have shown that, like rimonabant, Tetrahydrocannabivarin reduces weight gain and food consumption in non-fasted mice but does not increase activity in the brain regions involved in emotion regulation. In another study, involving diet-induced obese mice, oral Tetrahydrocannabivarin reduced body fat content, increased energy expenditure, and reduced fasting insulin and 30-min insulin response to oral glucose tolerance test. In clinical trials THCV significantly decreased fasting plasma glucose and improved pancreatic β-cell function.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Inocoterone acetate (USAN) (also known as RU-38882, RU-882) is the acetate ester of inocoterone a steroid-like nonsteroidal antiandrogen (NSAA) that was developed for topical administration to treat acne but was never marketed. Inocoterone acetate is actually not a silent antagonist of the androgen receptor but rather a weak partial agonist, similarly to steroidal antiandrogens like cyproterone acetate. In this double-blind study of 126 male subjects with acne, a topical solution of the antiandrogen inocoterone produced a modest but statistically significant reduction in the number of inflammatory acne lesions.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Thiphencillin is a penicillin analog patented by Abbott Laboratories as an antibacterial agent. Thiphencillin shows potent antibacterial activity against various species and genera of pathogenic bacteria.
Status:
Excipient
Class (Stereo):
CHEMICAL (ACHIRAL)
Oil orange SS (or FD&C orange No. 2), an azo compound that was studied as a food color. It was found that the Oil orange SS could lead to the tumors, carcinomas of the bladder.
Status:
Designated
Source:
FDA ORPHAN DRUG:1016024
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:1018524
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
FDA ORPHAN DRUG:46190
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Growth hormone releasing hexapeptide (GHRP-6) is a synthetic met-enkephalin analog that induces the release of growth hormone in vivo through binding of the ghrelin receptor. GHRP-6 increases proliferation in astrocytes through a mechanism that involves PI3K/Akt signaling. GHRP-6 also inhibits development of restraint stress-induced gastric lesions and reverses ovariectomy-induced effects on serum glucose and insulin levels. Additionally, GHRP-6 decreases locomotor activity and increases food intake in vivo. Essentially a synthetic version of ghrelin analogue, GHRP-6 (like GHRP-2) stimulates the release of an endogenous growth hormone (GH) within the somatotropes of the anterior pituitary in the animal and human body. Specifically, GHRP-6 will increase the number of somatotropes in a GH pulse by limiting the amount of somatostatin present, while standard GHRH increases the amplitude at which the pituitary cells pulse. Unlike ghrelin, GHRP-6 is not specifically used to increase appetite, but it may have secondary actions that impact hypothalamic neurons. These effects last for approximately an hour after the initial application, which mimics the natural application of GH, and consists of an eight hour circulation period.
In studies GHRP-6 has shown biological actions similar to the naturally occurring hunger stimulating peptide ghrelin. Its main use is to promote food intake by stimulating hunger and aid in energy metabolism. It can be used in the treatment of GH deficiency as well as cachexia, eating disorders and obesity. GHRP-6 is a synthetic met-enkephalin (a naturally occurring opioid growth factor) analog. GHRP-6 contains D-amino acids that are entirely synthetic, lacks opioid activity, and shares no sequence relation with GHRH. It has also been shown that GHRP-6 can lead to re-stimulation of the natural production of HGH.
Studies have shown that GHRP-6 increases the secretion of IGF-1 (InsulinLike Growth Factor 1) by the liver, which is speculated to be a required component in the anabolic mechanisms leading to the action of HGH. It also appears that GHRP-6 has positive implications for the central nervous system, as ghrelin is known to protect neurons.
Status:
Designated
Source:
FDA ORPHAN DRUG:918622
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
